Literature DB >> 22154948

Severe acute autoimmune hepatitis after natalizumab treatment.

Andrea Lisotti, Francesco Azzaroli, Stefano Brillanti, Giuseppe Mazzella.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22154948     DOI： 10.1016/j.dld.2011.11.003

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN： 1590-8658            Impact factor:   4.088


× No keyword cloud information.
  13 in total

Review 1.  Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?

Authors:  Tim Raine
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

2.  Liver Damage and Mortality in a Male Lewis Rat of Experimental Autoimmune Encephalomyelitis.

Authors:  Ameneh Ghaffarinia; Cyrus Jalili; Ali Mostafaie; Shahram Parvaneh; Nafiseh Pakravan
Journal:  Iran J Pathol       Date:  2015

Review 3.  Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; George K Koukoulis; George N Dalekos
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

4.  Acute Hepatitis with Positive Autoantibodies: A Case of Natalizumab-Induced Early-Onset Liver Injury.

Authors:  Marlone Cunha-Silva; Priscilla Brito Sena de Moraes; Pedro Rodrigues de Carvalho; Larissa Bastos Eloy da Costa; Guilherme Rossi Assis-Mendonça; Cristina Alba Lalli; Gisele Conte Alves Fernandes; Fernanda Bocchi Monteiro; Gustavo Manginelli Lamas; Alfredo Damasceno; Daniel Ferraz de Campos Mazo; Tiago Sevá-Pereira
Journal:  Am J Case Rep       Date:  2022-06-29

5.  Psoriasis during natalizumab treatment for multiple sclerosis.

Authors:  Jorge Millán-Pascual; Laura Turpín-Fenoll; Pablo Del Saz-Saucedo; Ignacio Rueda-Medina; Santiago Navarro-Muñoz
Journal:  J Neurol       Date:  2012-10-25       Impact factor: 4.849

Review 6.  Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Authors:  Adnan M Subei; Daniel Ontaneda
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

7.  Fatal acute liver failure with hepatitis B virus infection during nataluzimab treatment in multiple sclerosis.

Authors:  Machteld E Hillen; Stuart D Cook; Arun Samanta; Evan Grant; James R Quinless; Jamuna K Rajasingham
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-02-12

Review 8.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

Review 9.  Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.

Authors:  Eva Havrdova; Jeffrey A Cohen; Dana Horakova; Ivana Kovarova; Eva Meluzinova
Journal:  Ther Clin Risk Manag       Date:  2017-10-16       Impact factor: 2.423

Review 10.  Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.

Authors:  Raquel Planas; Roland Martin; Mireia Sospedra
Journal:  Patient Relat Outcome Meas       Date:  2014-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.